Els K. Vanhoutte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Els K. Vanhoutte has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Catharina G. Faber
1 shared publication- Catharina Gerritdina Faber
Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
1 shared publication - Ingemar S. J. Merkies
Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands
1 shared publication Ingemar S.J. Merkies
1 shared publication
Latest Publications
- 1 November 2013
- Published by Elsevier in Neuromuscular Disorders
- Vol. 23 (11) , 924-933
196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8–10 February 2013, Naarden, The Netherlands
- 1 November 2013
- Published by Elsevier in Neuromuscular Disorders
- Vol. 23 (11) , 924-933
196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8–10 February 2013, Naarden, The Netherlands
- 1 January 2010
- Vol. 154, A2516
[Statistical significance or clinical relevance?].
This article evaluates the concept of 'minimal clinically important difference' (MCID) through the results of two studies. The first study was a randomised trial in patients with Parkinson's disease claiming a positive effect of treatment with rasagiline over placebo, based on statistical differences in ordinal outcome measures. However, the clinical relevance of the findings according to the concept of MCID was not taken into consideration. In the second study, MCIDs were defined by several methods in a large trial in patients with chronic inflammatory demyelinating polyneuropathy receiving intravenous immunoglobulin (IGIV) or placebo. In that study, the differences in outcomes between the intervention group and the placebo group were not only statistically significant, but also clinically relevant, in favour of the intervention group. This was demonstrated using various MCID cut-off values.
- 1 January 2010
- Vol. 154, A2516
[Statistical significance or clinical relevance?].
This article evaluates the concept of 'minimal clinically important difference' (MCID) through the results of two studies. The first study was a randomised trial in patients with Parkinson's disease claiming a positive effect of treatment with rasagiline over placebo, based on statistical differences in ordinal outcome measures. However, the clinical relevance of the findings according to the concept of MCID was not taken into consideration. In the second study, MCIDs were defined by several methods in a large trial in patients with chronic inflammatory demyelinating polyneuropathy receiving intravenous immunoglobulin (IGIV) or placebo. In that study, the differences in outcomes between the intervention group and the placebo group were not only statistically significant, but also clinically relevant, in favour of the intervention group. This was demonstrated using various MCID cut-off values.